Portfolio Category: Exits

Phase Four

Ventyx Biosciences

Developing selective inhibitors of TYK2 for autoimmune diseases.

Seahorse Bioscience

Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.

K2M

Acquired by Welsh, Carson, Anderson & Stowe. Developer of solutions for the treatment of complex spinal pathologies.

FlowCardia

Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.

Dezima

Acquired by Amgen. Focused on the development of a small molecule therapy for dyslipidemia.

Conor Medsystems

Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.

Ception

Acquired by Cephalon. Focused on the development of a biologic therapy for the treatment of asthma.

Biovex

Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.

Akarna Therapeutics

Acquired by Allergan. Focused on the development of a small molecule therapy for the treatment of NASH.

Therox

Acquired by Zoll Medical. Developer of SuperSaturated Oxygen (SSO2) therapy to complement percutaneous coronary intervention.

Ovizio Imaging Systems

Provider of digital holographic microscopy technology.